{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:27:20Z","timestamp":1781663240452,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016650","name":"Rare Diseases Clinical Research Network","doi-asserted-by":"publisher","award":["NIH U54 NS115054"],"award-info":[{"award-number":["NIH U54 NS115054"]}],"id":[{"id":"10.13039\/100016650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00415-026-13670-y","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:15:12Z","timestamp":1774282512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Half a century of change: demographic trends and their clinical impact in acetylcholine receptor antibody-positive myasthenia gravis"],"prefix":"10.1007","volume":"273","author":[{"given":"Silvia","family":"Falso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Spagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Emilio","family":"Alboini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Damato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0282-8787","authenticated-orcid":false,"given":"Amelia","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"13670_CR1","doi-asserted-by":"publisher","first-page":"210139","DOI":"10.1212\/WNL.0000000000210139","volume":"104","author":"J JulJarb\u00e6k Nielsen","year":"2024","unstructured":"JulJarb\u00e6k Nielsen J, Levison L, Andersen H (2024) Changes in myasthenia gravis incidence in Denmark from 1985 to 2021: a nationwide population-based study. Neurology 104(1):210139. https:\/\/doi.org\/10.1212\/WNL.0000000000210139","journal-title":"Neurology"},{"issue":"5","key":"13670_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neurol.2024.02.392","volume":"180","author":"S Keovilayhong","year":"2024","unstructured":"Keovilayhong S, Mulliez A, Feral L et al (2024) Epidemiology of myasthenia gravis in France: incidence, prevalence, and comorbidities based on national healthcare insurance claims data. Rev Neurol 180(5):451\u2013458. https:\/\/doi.org\/10.1016\/j.neurol.2024.02.392","journal-title":"Rev Neurol"},{"key":"13670_CR3","doi-asserted-by":"publisher","first-page":"1203679","DOI":"10.3389\/fneur.2023.1203679","volume":"14","author":"KJ Herr","year":"2023","unstructured":"Herr KJ, Shen SP, Liu Y, Yang CC, Tang CH (2023) The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. Front Neurol 14:1203679. https:\/\/doi.org\/10.3389\/fneur.2023.1203679","journal-title":"Front Neurol"},{"key":"13670_CR4","doi-asserted-by":"publisher","first-page":"1339167","DOI":"10.3389\/fneur.2024.1339167","volume":"15","author":"Y Ye","year":"2024","unstructured":"Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA (2024) Epidemiology of myasthenia gravis in the United States. Front Neurol 15:1339167.\u00a0https:\/\/doi.org\/10.3389\/fneur.2024.1339167","journal-title":"Front Neurol"},{"issue":"2","key":"13670_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga AR, Paul M, Heckmann JM, Guptill JT, Evoli A (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol 21(2):176\u2013188. https:\/\/doi.org\/10.1016\/S1474-4422(21)00297-0","journal-title":"Lancet Neurol"},{"key":"13670_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.irn.2025.04.028","volume":"182","author":"NE Gilhus","year":"2025","unstructured":"Gilhus NE, Breiner A (2025) Chapter eight - Epidemiology of myasthenia gravis. Int Rev Neurobiol 182:161\u2013196.\u00a0https:\/\/doi.org\/10.1016\/bs.irn.2025.04.028","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"13670_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"13670_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"issue":"2","key":"13670_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916","volume":"20","author":"I Raffaele","year":"2024","unstructured":"Iorio R (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20(2):84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916","journal-title":"Nat Rev Neurol"},{"key":"13670_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.78017","author":"B Roy","year":"2025","unstructured":"Roy B,\u00a0Chen J, Khani-Habibabadi F et al (2025) A distinct immunological signature in late-onset myasthenia gravis: insights from an exploratory proteomics study. Ann Neurol.\u00a0https:\/\/doi.org\/10.1002\/ana.78017 Online ahead of print","journal-title":"Ann Neurol"},{"issue":"2","key":"13670_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000529583","volume":"57","author":"H Wartmann","year":"2023","unstructured":"Wartmann H, Hoffmann S, Ruck T, Nelke C, Deiters B, Volmer T (2023) Incidence, prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: a 10-year real-world data analysis of German claims data. Neuroepidemiology 57(2):121\u2013128. https:\/\/doi.org\/10.1159\/000529583","journal-title":"Neuroepidemiology"},{"issue":"5","key":"13670_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mus.27331","volume":"64","author":"JLS Thomsen","year":"2021","unstructured":"Thomsen JLS, Vinge L, Harbo T, Andersen H (2021) Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve 64(5):538\u2013544. https:\/\/doi.org\/10.1002\/mus.27331","journal-title":"Muscle Nerve"},{"key":"13670_CR13","doi-asserted-by":"publisher","first-page":"175628642513447","DOI":"10.1177\/17562864251344742","volume":"18","author":"F Beeching","year":"2025","unstructured":"Beeching F, Lecchi A, Riccitelli GC (2025) Female gender and quality of life outcomes in myasthenia gravis: a systematic review and meta-analysis. Ther Adv Neurol Disord 18:17562864251344742. https:\/\/doi.org\/10.1177\/17562864251344742","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"13670_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/wnl.26.11.1054","volume":"25","author":"JM Lindstrom","year":"1998","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1998) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26(11):1054\u20131059.\u00a0https:\/\/doi.org\/10.1212\/wnl.26.11.1054","journal-title":"Neurology"},{"issue":"1","key":"13670_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00313202","volume":"224","author":"E Bartoccioni","year":"1980","unstructured":"Bartoccioni E, Scuderi F, Scoppetta C et al (1980) Myasthenia gravis, thymectomy, and antiacetylcholine receptor antibody. J Neurol 224(1):9\u201315. https:\/\/doi.org\/10.1007\/BF00313202","journal-title":"J Neurol"},{"issue":"9","key":"13670_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","volume":"93","author":"V Damato","year":"2022","unstructured":"Damato V, Spagni G, Monte G et al (2022) Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 93(9):995\u20131000. https:\/\/doi.org\/10.1136\/jnnp-2022-329284","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"13670_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology."},{"issue":"6","key":"13670_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C et al (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 40(6):1111\u20131124. https:\/\/doi.org\/10.1007\/s10072-019-03746-1","journal-title":"Neurol Sci"},{"issue":"3","key":"13670_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P,\u00a0Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"1\u20132","key":"13670_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000500268","volume":"53","author":"P Maddison","year":"2019","unstructured":"Maddison P, Ambrose PA, Sadalage G, Vincent A (2019) A prospective study of the incidence of myasthenia gravis in the east Midlands of England. Neuroepidemiology 53(1\u20132):93\u201399. https:\/\/doi.org\/10.1159\/000500268","journal-title":"Neuroepidemiology"},{"issue":"10","key":"13670_CR21","doi-asserted-by":"publisher","first-page":"E1426","DOI":"10.1212\/WNL.0000000000010209","volume":"95","author":"M Tomschik","year":"2020","unstructured":"Tomschik M,\u00a0Hilger E, Rath J et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95(10):e1426\u2013e1436. https:\/\/doi.org\/10.1212\/WNL.0000000000010209","journal-title":"Neurology"},{"issue":"4","key":"13670_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/mus.24348","volume":"51","author":"B Mombaur","year":"2015","unstructured":"Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM (2015) Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa. Muscle Nerve 51(4):533\u2013537. https:\/\/doi.org\/10.1002\/mus.24348","journal-title":"Muscle Nerve"},{"key":"13670_CR23","unstructured":"\u2018https:\/\/demo.istat.it\/\u2019."},{"key":"13670_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","volume":"196","author":"D Ray","year":"2018","unstructured":"Ray D, Yung R (2018) Immune senescence, epigenetics and autoimmunity. Clin Immunol 196:59\u201363. https:\/\/doi.org\/10.1016\/j.clim.2018.04.002","journal-title":"Clin Immunol"},{"key":"13670_CR25","doi-asserted-by":"publisher","first-page":"123314","DOI":"10.1016\/j.jns.2024.123314","volume":"468","author":"V Bril","year":"2025","unstructured":"Bril V, Gilhus NE (2025) Aging and infectious diseases in myasthenia gravis. J Neurol Sci 468:123314. https:\/\/doi.org\/10.1016\/j.jns.2024.123314","journal-title":"J Neurol Sci"},{"issue":"1","key":"13670_CR26","doi-asserted-by":"publisher","first-page":"10317","DOI":"10.1038\/s41467-024-54097-1","volume":"15","author":"W Xu","year":"2024","unstructured":"Xu W,\u00a0Yan VKC, Zhang Z et al (2024) Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study. Nat Commun 15(1):10317.\u00a0https:\/\/doi.org\/10.1038\/s41467-024-54097-1","journal-title":"Nat Commun"},{"issue":"11","key":"13670_CR27","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E,\u00c1lvarez-Velasco R, Segovia S\u00a0et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94(11):e1171\u2013e1180. https:\/\/doi.org\/10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"issue":"5","key":"13670_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/mus.28077","volume":"69","author":"E Sechi","year":"2024","unstructured":"Sechi E,\u00a0Deiana GA, Puci M et al (2024) Epidemiology of seropositive myasthenia gravis in Sardinia: a population-based study in the district of Sassari. Muscle Nerve\u00a069(5):637\u2013642. https:\/\/doi.org\/10.1002\/mus.28077","journal-title":"Muscle Nerve"},{"issue":"6","key":"13670_CR29","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/01.wnl.0000176067.32186.a3","volume":"65","author":"FE Somnier","year":"2005","unstructured":"Somnier FE (2005) Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65(6):928\u201330. https:\/\/doi.org\/10.1212\/01.wnl.0000176067.32186.a3","journal-title":"Neurology"},{"issue":"4","key":"13670_CR30","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s10072-024-07920-y","volume":"46","author":"AG Vakrakou","year":"2025","unstructured":"Vakrakou AG, Strataki E, Lymperopoulos L, Panaretos D, Zouvelou V (2025) Phenotypic patterns and response to immunotherapy in a group of very late onset myasthenia gravis: a single center study. Neurol Sci 46(4):1833\u20131842. https:\/\/doi.org\/10.1007\/s10072-024-07920-y","journal-title":"Neurol Sci"},{"issue":"3","key":"13670_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","volume":"23","author":"P Narayanaswami","year":"2024","unstructured":"Narayanaswami P, Sanders DB, Thomas L et al (2024) Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. Lancet Neurol 23(3):267\u2013276. https:\/\/doi.org\/10.1016\/S1474-4422(24)00028-0","journal-title":"Lancet Neurol"},{"issue":"2","key":"13670_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","volume":"80","author":"F Baggi","year":"2013","unstructured":"Baggi F, Andreetta F, Maggi L et al (2013) Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 80(2):188\u2013195. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b907b","journal-title":"Neurology"},{"key":"13670_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D (2018) Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol\u00a040:83\u201394.\u00a0https:\/\/doi.org\/10.1016\/j.smim.2018.10.010","journal-title":"Semin Immunol"},{"key":"13670_CR34","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop T,\u00a0Larbi A, Dupuis G et al (2018) Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol\u00a08:1960.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2017.01960","journal-title":"Front Immunol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13670-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:48:47Z","timestamp":1776649727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13670"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13670-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.F. has received speaker honoraria from Alexion, Argenx, UCB. G.S. has received public speaking honoraria\u00a0and\/or\u00a0consultation fees\u00a0from Argenx, Alexion, and AMGEN. S.M. has received speaker honoraria from Alexion and UCB. P.E.M. has received support for attending scientific meetings and speaker honoraria from Amgen, UCB, Alexion, Argenx. V.D. has received public speaking honoraria and compensation for advisory boards and\/or consultation fees from UCB, Alexion, Dianthus, and Roche. A.E. has received consultancy fees and speaker honoraria from Grifols, UCB, Alexion. R.I. has received consultancy fees and speaker honoraria from Alexion, Amgen, Argenx, Johnson&Johnson, Merck, UCB and Dianthus Therapeutics. The remaining authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"227"}}